Antibody response 6 months after the booster dose of Pfizer in previous recipients of CoronaVacArticle Published on 2023-01-012023-07-10 Journal: Journal of medical virology [Category] COVID19(2023년), [키워드] antibodies BNT162b2 vaccine booster dose. CoronaVac COVID-19 vaccine SARS-CoV-2 [DOI] 10.1002/jmv.28169 PMC 바로가기
Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan일본 의료 센터에서 BNT162b2 mRNA COVID-19 백신의 효과 및 돌파구에 대한 실제 증거Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] Asia Asian BNT162b2 BNT162b2 vaccine breakthrough COVID-19 vaccine delta variant demonstrated Effectiveness Effectiveness. Evidence evidence of hospital hygiene Infection infection control Japan measure mRNA of BNT162b2 Population populations Public hygiene Regulation required retrospective cohort study SARS-CoV-2 Spread Tokyo vaccination Vaccine variant while [DOI] 10.1080/21645515.2021.1984124 PMC 바로가기 [Article Type] Article
Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2Article Published on 2022-12-222023-07-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), [키워드] antiphospholipid antibodies APS autoantibodies BNT162b2 vaccine COVID-19 healthcare professionals. SARS-CoV-2 [DOI] 10.3390/ijms24010211 PMC 바로가기
The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levelsArticle Published on 2022-12-012023-07-10 Journal: Immunologic research [Category] COVID19(2023년), [키워드] ANA titers APS antibodies Autoimmune Autoimmune dysregulation BNT162b2 vaccine COVID-19 mRNA vaccines. [DOI] 10.1007/s12026-022-09309-5 PMC 바로가기
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection3회분의 BNT162b2 백신 또는 BA.1 감염에 의한 Omicron 하위 계통 및 Deltacron SARS-CoV-2 중화Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Antibody neutralization BNT162b2 BNT162b2 vaccine contribute convalescent sera dose evade geometric mean geometric mean titre geometric mean titres GMT GMTs highest Identifier immune immune evasion individual infected individual infected individuals Infection Mutation neutralization neutralization activity neutralized of BNT162b2 omicron post-dose SARS-CoV-2 SARS-CoV-2 spike sera titre Trial registration unique USA-WA1/2020 vaccinated individual Vaccine variant variants variants. [DOI] 10.1080/22221751.2022.2099305 PMC 바로가기 [Article Type] Article
Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccinesArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Ad26.COV2.S Ad26.COV2.S vaccine antibody B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta BNT162b2 BNT162b2 vaccine booster center contributed Control COVID-19 Delta dose Effectiveness elicited faster FIVE Gamma immunization moderate mRNA-1273 mRNA-based vaccine Mutation Neutralizing Neutralizing antibodies neutralizing antibody omicron P.1 postvaccination prevention Protein pseudovirus receiving recipient recommendation robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant subject Support vaccination Vaccine vaccine efficacy variants of concern variants of concern (VOCs). VoC VOCs wild type [DOI] 10.1002/jmv.28032 PMC 바로가기
SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort studyArticle Published on 2022-12-012022-10-06 Journal: Lancet Reg Health Am [Category] 진단, [키워드] age All participant anti-SARS-CoV-2 BNT162b2 BNT162b2 vaccine booster Care cohort study CoronaVac COVID-19 determine dose effective end point General population groups Heterologous heterologous vaccine homologous humoral immune response IFN-γ IgG antibody IL-2 inactivated kidney liver median Medicine more difficult mRNA mRNA vaccine neutralising antibody not differ of BNT162b2 outcome Patient priming proportion Prospective prospective cohort study recipient recipients Red SARS-CoV-2 SARS-CoV-2 vaccine School secondary secreting significantly significantly higher solid organ solid organ transplant SOT T-cell T-cell responses vaccination Vaccine vaccine immunogenicity. women [DOI] 10.1016/j.lana.2022.100371 PMC 바로가기 [Article Type] Article
Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccinesCOVID-19 백신 접종 후 면역 장수: 현재 승인된 백신에 대한 종합 검토Review Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] Ad26.COV2.S anti-Spike IgG antibody antibody persistence approved Asymptomatic AZD1222 BNT162b1 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines booster dose Cell-mediated immunity COVID-19 COVID-19 vaccination detectable first dose Humoral immunity IgA antibodies immune response Immunity immunogenicity induce long-term immunity Long-term protection Longevity mRNA-1273 mRNA-1273 vaccine neutralizing effect peaked persistence Perspective produced provide SARS-CoV-2 Spread systematic review T-cell T-cell immunity T-cell Response Vaccine Vaccines. [DOI] 10.1080/21645515.2022.2037384 PMC 바로가기 [Article Type] Review
The association between adverse reactions and immune response against SARS-CoV-2 spike protein after vaccination with BNT162b2 among healthcare workers in a single healthcare system: a prospective observational cohort study단일 의료 시스템에서 의료 종사자들 사이에서 BNT162b2 백신 접종 후 SARS-CoV-2 스파이크 단백질에 대한 부작용과 면역 반응 사이의 연관성: 전향적 관찰 코호트 연구Observational Study Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, SARS, 임상, 진단, [키워드] administration Adverse Adverse reaction Anti-spike IgG antibody anti-spike IgG level Antibody titer association Asthma BNT162b2 BNT162b2 vaccine conducted COVID-19 Cutoff determine Factor first dose healthcare healthcare worker help humoral humoral immune response Humoral response IgG IgG level immune response information Local majority median median age mRNA mRNA vaccine of BNT162b2 participant Participants prospective observational cohort reaction recipients recruited reported SARS-CoV-2 anti-spike IgG SARS-CoV-2 spike protein second dose significantly higher systemic adverse reactions Systemic adverse reactions. systemic reaction vaccination Vaccine was collected were measured with COVID-19 women [DOI] 10.1080/21645515.2022.2048559 PMC 바로가기 [Article Type] Observational Study
Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature ReviewArticle Published on 2022-11-032022-11-15 Journal: Laboratory medicine [Category] 진단, [키워드] Acquired ADAMTS Anemia autoantibody Blood BNT162b2 BNT162b2 vaccine caplacizumab caused Complete COVID-19 COVID-19 vaccine deficiency Diagnosis gastrointestinal symptoms immunosuppressive literature microangiopathy MOST occurred outcome Patient patients Pfizer-BioNTech plasma positive Prednisone presenting report reported review second dose significantly the patient therapy thrombocytopenia thrombosis thrombotic Thrombotic thrombocytopenic purpura treated Treatment Vaccine vaccine. was used [DOI] 10.1093/labmed/lmac016 PMC 바로가기